This is a correction to Pharmaceuticals 2009, 2(3), 118-124.

Pharmaceuticals 2011, 4(10), 1293-1294; doi:10.3390/ph4101293
Correction

Novo, S. et al. Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors? Pharmaceuticals 2009, 2, 118-124

Department of Internal Medicine and Cardiovascular Diseases, University Hospital “Paolo Giaccone”, University of Palermo, Italy
* Author to whom correspondence should be addressed.
Received: 14 September 2011; Published: 30 September 2011
PDF Full-text Download PDF Full-Text [123 KB, uploaded 30 September 2011 10:16 CEST]
Abstract: In the published version “Paladini et al. reported that aliskiren 300 mg provided a sustained BP-lowering effect beyond the 24-h dosing interval, with a significantly smaller loss of BP-lowering effect in the 24-48 h period after dose than irbesartan 300 mg or ramipril 10 mg [25]”. Paladini et al. should be Palatini et al., and the cited reference number should be [10], not [25].. In the sentence, “Early data suggest a role for aliskiren in preventing end-organ damage but, considering the ONTARGET results with an ACE-I-ARB combination, outcome studies are needed before the use of aliskiren can be recommended in combination with other RAS inhibitors [18–30]” one more citation number was added [5], so the revised sentence is “Early data suggest a role for aliskiren in preventing end-organ damage but, considering the ONTARGET results with an ACE-I-ARB combination, outcome studies are needed before the use of aliskiren can be recommended in combination with other RAS inhibitors [5,18–30]”. [...]

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Novo, S.; Fazio, G.; Raccuglia, E.; Mignano, A.; Novo, G. Novo, S. et al. Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors? Pharmaceuticals 2009, 2, 118-124. Pharmaceuticals 2011, 4, 1293-1294.

AMA Style

Novo S, Fazio G, Raccuglia E, Mignano A, Novo G. Novo, S. et al. Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors? Pharmaceuticals 2009, 2, 118-124. Pharmaceuticals. 2011; 4(10):1293-1294.

Chicago/Turabian Style

Novo, Salvatore; Fazio, Giovanni; Raccuglia, Elena; Mignano, Antonino; Novo, Giuseppina. 2011. "Novo, S. et al. Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors? Pharmaceuticals 2009, 2, 118-124." Pharmaceuticals 4, no. 10: 1293-1294.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert